Concepedia

Lynda Grinsted

LG

Statistics

Publications

13

Citations

2.6K

H-Index

13

Active since

2011

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

Edinburgh Cancer Research

Dana-Farber Cancer Institute

Royal Marsden Hospital

Lynda Grinsted is an author at AstraZeneca (United Kingdom) specializing in cancer pharmacology, pharmacology, and oncology.

Publications per year

2011–2023

13

Publications

13

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · New England Journal of Medicine · 2023 · 704 citations · Full text

, , +16

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Pasi A. Jänne, Alice T. Shaw, José Rodrigues Pereira et al. · The Lancet Oncology · 2012 · 657 citations

, , +11

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Ekaterina Trishkina, Mikhail Dvorkin et al. · The Lancet · 2016 · 602 citations · Full text

, , +14

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Darren Hodgson, Brian Dougherty, Zhongwu Lai et al. · British Journal of Cancer · 2018 · 232 citations · Full text

, , +17

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

Aung Naing, Carol Aghajanian, Éric Raymond et al. · British Journal of Cancer · 2012 · 128 citations · Full text

, , +16

1–5 of 13